Responses
Clinical/translational cancer immunotherapy
Original research
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
Compose a Response to This Article
Other responses
No responses have been published for this article.